Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

331 ARTÍCULOS , VIENDO DEL 211 AL 225

Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?

Banik A, Brown RE, Bamburg J, Lahiri DK, Khurana D, Friedland RP, Chen W, Ding Y, Mudher A, Padjen AL, Mukaetova-Ladinska E, Ihara M, Srivastava S, Padma Srivastava MV, Masters CL, Kalaria RN, Anand A.

J Alzheimers Dis. 2015;47(4):815-43. doi: 10.3233/JAD-150136.

Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial

Rea R, Carotenuto A, Traini E, Fasanaro AM, Manzo V, Amenta F.

J Alzheimers Dis. 2015;48(2):377-83. doi: 10.3233/JAD-141983.

Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study

Gauthier S, Rountree S, Finn B, LaPlante B, Weber E, Oltersdorf T.

J Alzheimers Dis. 2015;48(2):473-81. doi: 10.3233/JAD-150414.

Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS)

Matsuzono K, Sato K, Kono S, Hishikawa N, Ohta Y, Yamashita T, Deguchi K, Nakano Y, Abe K.

J Alzheimers Dis. 2015;48(3):757-63. doi: 10.3233/JAD-150518.

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease

Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;47(1):205-14. doi: 10.3233/JAD-142508.

Synthetic Curcumin Analogs as Inhibitors of β -Amyloid Peptide Aggregation: Potential Therapeutic and Diagnostic Agents for Alzheimer's Disease

Bukhari SN, Jantan I.

Mini Rev Med Chem. 2015;15(13):1110-21. doi: 10.2174/138955751513150923101841.

Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses

Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown RG, Banerjee S, Adams J, Johnson T, Bentham P, Phillips PP.

Lancet Neurol. 2015 Dec;14(12):1171-81. doi: 10.1016/S1474-4422(15)00258-6. Epub 2015 Oct 27.

[A comparison of the efficacy and safety of memantal and original memantine in the treatment of mild and moderate dementia in Alzheimer's disease]

Shiryaev OY, Shapovalov DL, Polozova TM, Goncharova OV, Kuznetsova NA, Cherenkova EV, Fedorova EY.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(10):56-61. doi: 10.17116/jnevro201511510156-61.

Novel potential for the management of Alzheimer disease

Ginter E, Simko V, Weinrebova D, Ladecka Z.

Bratisl Lek Listy. 2015;116(10):580-1. doi: 10.4149/bll_2015_112.

Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial

Henderson VW, Ala T, Sainani KL, Bernstein AL, Stephenson BS, Rosen AC, Farlow MR.

Neurology. 2015 Dec 1;85(22):1937-44. doi: 10.1212/WNL.0000000000002171. Epub 2015 Nov 4.

The Effects of Aerobic Exercise on Cognitive Function of Alzheimer's Disease Patients

Yang SY, Shan CL, Qing H, Wang W, Zhu Y, Yin MM, Machado S, Yuan TF, Wu T.

CNS Neurol Disord Drug Targets. 2015;14(10):1292-7. doi: 10.2174/1871527315666151111123319.

Aging process, cognitive decline and Alzheimer`s disease: can strength training modulate these responses?

Portugal EM, Vasconcelos PG, Souza R, Lattari E, Monteiro-Junior RS, Machado S, Deslandes AC.

CNS Neurol Disord Drug Targets. 2015;14(9):1209-13. doi: 10.2174/1871527315666151111121749.

An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy

Ashraf GM, Tabrez S, Jabir NR, Firoz CK, Ahmad S, Hassan I, Alexiou A, Kamal MA.

Curr Drug Metab. 2015;16(8):719-27. doi: 10.2174/138920021608151107125757.

WAVEFORM WINDOW #30. A Case of Nocturnal Episodes

Ardeshna N.

Neurodiagn J. 2015 Sep;55(3):195-200. doi: 10.1080/21646821.2015.1074494.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias